公司資料
Bicycle Therapeutics 股價、新聞與催化劑
- 股票代碼:
- BCYC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom with U
股票表現
3.79 USD (-5.49%)
收盤價
最後更新: 2026年10月6日
300M USD
市值
股價為何變動
截至 2026年10月6日，BCYC 下跌 5.49%，收於 $3.79。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Bicyclic Peptide Therapeutics Platform
Bicycle Therapeutics develops medicines built from proprietary bicyclic peptides that bind defined disease targets with antibody-like affinity while retaining small-molecule-like size. The platform supports drug conjugates, radioconjugates, imaging agents, and other precision-targeted modalities.
Nuzefatide Pevedotin
Nuzefatide pevedotin is an EphA2-targeting Bicycle Drug Conjugate carrying a cytotoxic payload. The program is being evaluated in recurrent pancreatic ductal adenocarcinoma and has also generated clinical and preclinical evidence across urothelial, head and neck, and other EphA2-expressing cancers.
Zelenectide Pevedotin
Zelenectide pevedotin targets Nectin-4 and is being studied alone and with pembrolizumab in metastatic urothelial cancer. Its design seeks to preserve antitumor activity while reducing toxicities associated with larger antibody-drug conjugates against the same target.
Bicycle Radioconjugates
The company is expanding into radiopharmaceuticals through Bicycle Radioconjugates, which use rapid tumor targeting and clearance characteristics to deliver radioisotopes. Human imaging studies are used to validate target engagement and support selection of therapeutic candidates.
Partnered Platform Economics
Bicycle also collaborates with pharmaceutical companies that apply its technology to targets outside the company's internally prioritized programs. These partnerships can provide research funding, milestones, and royalties while broadening validation of the underlying platform.
未來催化劑
- Clinical update from the Phase 2 study of nuzefatide pevedotin in recurrent pancreatic cancer as enrollment and follow-up mature.
- Initiation of the first company-sponsored Phase 1 trial of BT1702, an MT1-MMP-targeting Bicycle Radioconjugate, in 2027.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。